Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biotechnology company advancing a pipeline of oral small molecule degrader medicines based on targeted protein degradation (TPD). This news page aggregates company announcements, clinical updates, collaboration developments and capital markets activity related to Kymera’s work in immunological and other serious diseases.
Readers can follow detailed updates on KT-621, Kymera’s investigational first-in-class oral STAT6 degrader in Phase 2 clinical testing for Type 2 inflammatory diseases such as atopic dermatitis and asthma. News items include Phase 1b and Phase 2 trial progress, biomarker and clinical endpoint data, and regulatory milestones such as U.S. FDA Fast Track designation for moderate to severe atopic dermatitis. Coverage also extends to KT-579, an investigational oral IRF5 degrader for immune-mediated conditions, as it moves from preclinical work toward first-in-human studies.
In addition to internal programs, this feed highlights updates on Kymera’s partnered assets, including the IRAK4 degrader KT-485/SAR447971 in collaboration with Sanofi for immuno-inflammatory diseases and the oral CDK2 molecular glue degrader program with Gilead Sciences for potential use in breast cancer and other solid tumors. Investors can also find information on public offerings of common stock, shelf registration statements, and other corporate events disclosed through press releases and SEC filings.
By reviewing Kymera news on this page, users can track clinical trial milestones, regulatory interactions, collaboration announcements and financing transactions that shape the company’s development trajectory. For those researching KYMR stock or the evolution of targeted protein degradation in immunology and oncology, this consolidated news view provides ongoing context around Kymera’s pipeline and corporate strategy.
Summary not available.
Summary not available.
Summary not available.
Kymera Therapeutics (NASDAQ: KYMR) is set to report its first quarter 2023 financial results on May 4, 2023, with a conference call scheduled for 8:30 a.m. ET. The company, known for its innovative approach to targeted protein degradation, has outlined its participation in several upcoming investor conferences, including Stifel Virtual Targeted Oncology Days on April 25, 2023, BofA Securities Health Care Conference on May 10, 2023, and Piper Sandler Spring Biopharma Symposium on May 18, 2023. Kymera’s drug discovery engine focuses on targeting disease-causing proteins and aims to advance its therapeutic pipeline for various diseases, including immune-inflammatory diseases and hematologic malignancies.
Kymera Therapeutics (NASDAQ: KYMR), a biopharmaceutical company focused on targeted protein degradation, has announced upcoming investor events. The management team will participate in the Cowen 43rd Annual Health Care Conference in Boston, MA from March 6-8, 2023, with CEO Nello Mainolfi presenting a fireside chat on March 6 at 10:30 AM ET, alongside hosting 1x1 meetings. Additionally, the Jefferies Biotech on the Bay Summit in Miami, FL will take place on March 16-17, 2023, where the company will conduct 1x1 meetings only. A live webcast of the fireside chat will be available on their website.
Kymera Therapeutics (NASDAQ: KYMR) reported significant developments in its drug programs during its Q4 2022 results, highlighting continued progress in targeted protein degradation. The company plans to initiate Phase 2 trials for IRAK4 degrader KT-474, backed by a strong cash balance of approximately $560 million, ensuring funding through mid-2025. The KT-474 Phase 1 trials yielded positive results in treating hidradenitis suppurativa and atopic dermatitis. In addition, ongoing trials for KT-333 and KT-413 have shown promising early results. The company aims to launch the KT-253 Phase 1 trial in early 2023, further expanding its innovative pipeline.
Kymera Therapeutics (NASDAQ: KYMR) will announce its Q4 and full year 2022 financial results on February 23, 2023, followed by a conference call at 8:30 a.m. ET. The company focuses on targeted protein degradation to develop innovative therapies for challenging disease targets. Upcoming investor engagements include the Guggenheim Oncology Conference on February 8 and others through February 21. The company aims to advance therapies targeting IRAK4, IRAKIMiD, STAT3, and MDM2, with expectations to progress its clinical trials and maintain a solid financial runway into H2 2025.
X-Chem has expanded its collaboration with Kymera Therapeutics (NASDAQ: KYMR), now the primary provider of DNA-encoded library (DEL) screening services. The partnership covers 12 targets, granting Kymera exclusive rights to discovered compounds. This collaboration aims to enhance Kymera's efforts in developing innovative protein degraders, crucial for addressing challenging disease targets. Kymera's CEO praised X-Chem’s libraries for their quality and scientific rigor, reflecting a commitment to revolutionizing medicine through targeted protein degradation.
Kymera Therapeutics (NASDAQ: KYMR) announced its 2023 goals after a pivotal 2022, where its lead program KT-474 demonstrated an encouraging safety profile in inflammatory diseases. The company ended 2022 with approximately $560 million in cash, expected to fund operations into 2025. Major objectives for 2023 include initiating Phase 2 trials for KT-474, demonstrating clinical activity in oncology programs KT-413 and KT-333, and commencing Phase 1 trials for KT-253. The company aims to leverage its discovery platform to develop novel therapeutics targeting disease-causing proteins.
Kymera Therapeutics (NASDAQ: KYMR) appointed Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary. Chiniara brings extensive legal experience from biopharmaceutical companies and will oversee Kymera’s legal and governance functions. CEO Nello Mainolfi highlighted her leadership in advancing the company as it aims to become a fully integrated global biopharmaceutical entity. Chiniara previously served at Alexion Pharmaceuticals and Alere, enhancing legal operations and corporate social responsibility initiatives.